Detailed Narrative
Q3 FY26 Financial Performance Overview
Divi's Laboratories reported a consolidated total income of ₹2,692 crores for Q3 FY26, marking a 12.12% year-over-year increase from ₹2,401 crores. Profit before exceptional item📎s and tax rose by 17.63% YoY to ₹854 crores, compared to ₹726 crores in the prior year. However, profit after tax saw a slight decline of 1.02% YoY to ₹583 crores. The company also recorded a foreign exchange gain of ₹19 crores during the quarter.
Generics and Custom Synthesis Segment Performance
The Generics segment maintained stable performance, supported by strong backward integration and process efficiencies, despite a competitive pricing environment. Generics constituted 43% of the product mix in Q3 FY26. The Custom Synthesis segment, representing 57% of the product mix, is actively engaged in multiple RFPs and customer visits, with several projects progressing towards commercial volumes within the next year, with some expected to start moving in Q3/Q4 2027.
Nutraceuticals and Peptide Segment Growth
The Nutraceuticals segment delivered a healthy performance, contributing ₹214 crores to the Q3 FY26 revenue. For the nine-month period, nutraceutical revenue reached ₹706 crores, a 22.57% YoY growth from ₹576 crores. This year marks 20 years for Divi's Nutraceuticals, with ongoing capacity expansion. In the Peptide segment, Divi's continues to advance work in complex building blocks and fragments, supporting multiple customer programs across all clinical phases, leveraging decades of experience in protected amino acids.
Manufacturing and Unit 3 Strategy
Unit 3 at Kakinada is playing a crucial role in Divi's backward integration strategy, with operational blocks effectively used for starting materials and intermediates, strengthening the supply chain. Expansions and transfer activities are progressing as planned, with additional manufacturing blocks being developed. This strategy aims to free up capacity at Units 1 and 2 for new projects. The company also successfully concluded a U.S. FDA general CGMP inspection at its Unit 1 Choutuppal facility, reaffirming its commitment to quality and regulatory compliance.
Operational Efficiency and Risk Management
Operational efficiency improved, with material consumption as a percentage of sales revenue decreasing to 36.3% in Q3 FY26 from 39.8% YoY. Divi's is expanding its technology platforms, including process automation and new chemistry platforms, to enhance efficiency, improve process safety, and strengthen overall production. While raw material prices were broadly stable, management remains vigilant regarding potential pricing pressures from China's withdrawal of export tax rebates and continues to diversify its vendor base to mitigate supply risks.
Capital Expenditure and Future Outlook
Capitalized assets amounted to ₹313 crores in Q3 FY26, contributing to ₹776 crores for the nine-month period. Capital work in progress stood at ₹2,394 crores as of December 31, 2025, in line with ongoing capacity expansion and backward integration initiatives. The targeted capex for FY26 is ₹1,900 crores. The company aims to improve its asset turnover ratio to a range of 1.5 to 1.6 in the next 4-5 years, indicating efficient utilization of its growing asset base and a focus on long-term value creation.